Abstract
Vigabatrin (4-amino-5-hexenoic acid; gamma-vinyl GABA; GVG) is a rationally designed, specific enzyme-activated irreversible inhibitor of GABA transaminase (Lippert et al. 1977; Schechter et al. 1979). It is a molecular structural analogue of GABA with a vinyl appendage (Fig. 1) and is highly soluble in water but only slightly soluble in ethanol and methanol and is insoluble in hexane and toluene. It is a white to off-white crystalline solid with a melting point of 171°–177°C. Its molecular weight is 129.16 and the conversion factor (CF) is 7.75 (mg/l × CF = μmol/l).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aicardi J, Sabril IS Investigator and Peer Review Groups, Mumford JP, Dumas C, Wood S (1996) Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia 37:638–642
Appleton R (1995) Vigabatrin in the management of generalized seizures in children. Seizures 4:45–48
Arzimanoglou AA, Dumas C, Ghirardi L, and the French Neurologists Sabril Study Group (1997) Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. Seizure 6:225–231
Ben-Menachem E, Persson L, Schechter PJ et al. (1988) Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial seizures. Epilepsy Res 2:96–101
Ben-Menachem E, Persson LI, Schechter PJ et al. (1989) The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmac 27:79S–85S
Ben-Menachem E, Persson LI, Mumford JP (1991) Effect of long term vigabatrin therapy on selected CSF neurotransmitter concentrations. J Child Neurology 6 [Suppl 2]:11–16
Ben-Menachem E, Mumford J, Hamberger A (1993) Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system - a case study. Epilepsy Res 16:241–243
Beran RG, Berkovic SF, Buchanan N et al. (1996) A double-blind, placebo-controlled cross-over study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 5:259–265
Besser R, Kramer G (1989) Long-term efficacy and safety of vigabatrin in epileptic patients. 18th International Epilepsy Congress, New Dehli Book of Abstracts, p. 155
Browne TR, Mattson RH. Penry JK et al. (1987) Vigabatrin for refractory complex partial seizures. Multicenter single-blind study and long-term follow-up. Neurology 37:184–189
Browne TR, Mattson RH, Penry JK et al. (1991) Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures; an update. Neurology 41:363–364
Challier JC, Rey E, Binten T, Olive G (1992) Passage of S (+) and R (-) gamma-vinyl-GABA across the human isolated perfused placenta. Br J Clin Pharmac 34:139–143
Chiron C, Dulac O, Beaumont D et al. (1991) Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 6 [Suppl 2]:S52–S59
Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26:389–395
Cocito L, Maffini M, Perfumo P et al. (1989) Vigabatrin in complex partial seizures: a long-term study. Epilepsy Res 3:160–166
Cockerell C, Moriaty J, Trimble MR, Shorvon SD, Sander JWAS (1996) Epidemiological survey of acute psychological disorders in epilepsy. Epilepsy Res 25:119–131
de Bittencourt PRM, Mazer S, Marcourakis T, Bigarella MM, Ferreira ZS, Mumford JP (1994) Vigabatrin: clinical evidence supporting rational polytherapy in management of uncontrolled seizures. Epilepsia 35:373–380
Dijkstra JB, McGuire AM, Trimble MR (1992) The effect of vigabatrin on cognitive function and mood. Hum Psychopharmacol 7:329–323
Dodrill CB, Arnett JL, Sommerville KW, Sussman NM (1993) Evaluation of the effects of vigabatrin on cognitive abilities and quality of life. Neurology 43:2501–2507
Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Brit Med J 314:180–181
Faedda MT, Lani C, Paris L et al. (1989) Clinical results of vigabatrin treatment in patients with refractory epilepsy. In: Manelis J, Bental E, Loeber JN et al. (eds) Advances in epileptology. Raven Press, New York, pp. 170–171
Feucht M, Brantner-Inthaler S. (1994) Gamma-vinyl GABA (vigabatrin) in the therapy of Lennox-Gastaut Syndrome: an open study. Epilepsia 35:993–998
French JA, Mosier M, Walker K, Sommerville K, Sussman N and the Vigabatrin Protocol 024 Investigative Cohort (1996) A double-blind placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 46:54–61
Frisk-Holmberg M, Kerth P, Meyer P (1989) Effect of food on the absorption of vigabatrin. Br J Clin Pharmac 27:23S–25S
Gale K (1986) Role of the substantia nigra in GABA-mediated anticonvulsant actions. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ (eds) Basic mechanisms of the epilepsies. Molecular and cellular approaches. Adv Neurol 44:343–364
Gram L, Lyon BB, Dam M (1983) Gamma-vinyl GABA: a single-blind trial in patients with epilepsy. Acta Neurol Scand 68:34–39
Gram L, Klosterskov P, Dam M (1985) Gamma-vinyl GABA: a double-blind, placebo-controlled trial in partial epilepsy. Ann Neurol 17:262–266
Grant SM, Heel RC (1991) Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs 4:889–926
Gruenewald RA, Thompson PJ, Corcoran R et al. (1994) Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psych 57:1057–1063
Haegele KD, Schechter PJ (1986) Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmac Ther 40:581–586
Haegele KD, Huebert ND, Ebel M et al. (1988) Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharm and Therap 44:558–565
Herranz JL, Arteaga R, Farr IN et al. (1991) Dose-response study of vigabatrin in children with refractory epilepsy. J Child Neurol 6 [Suppl 2]:S45–S51
Hoke JF, Chi EM, Antony K et al. (1991) Effect of food on the bioavailability of vigabatrin tablets. Epilepsia 32 [Suppl 3):7
Jung MJ, Lippert B, Metcalf BW et al. (1977) Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. Neurochem 29:797–802
Kälviäinen R, Halonen T, Pitkänen A, Riekkinen PJ (1993) Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapy. J Neurochem 60:1244–1250
Kälviäinen R, Aikia M, Saukkonen AM et al. (1995) Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized controlled study. Arch Neurol 52:989–996
Kendall DA, Fox DA, Enna SJ (1981) Effects of gamma-vinyl GABA on bicuculline-induced seizures. Neuropharmacol 20:351–355
Lippert B, Metcalf B, Jung MJ, Casara P (1977) 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem 74:441–445
Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J (1989) Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharm 27 [Suppl 1]:109S–112S
Loiseau P, Hardenberg JP, Pestre M et al. (1986) Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug resistant epilepsy. Epilepsia 27:115–120
Lortie A, Chiron C, Mumford J, Dulac O (1993) The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 43:S24–S27
Luna D, Dulac O, Pajot N, Beaumont D (1989) Vigabatrin in the treatment of childhood epilepsies. A single-blind placebo controlled study. Epilepsia 30:430–437
Matsuo F, Bergen D, Faught E, Messenheimer JA et al. (1993) Placebo-controlled study of efficacy and safety of lamotrigine in patients with partial seizures. Neurology 43:2284–2291
Meldrum BS, Horton R (1978) Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, gamma-acetylenic GABA (4-amino-hex-5-ynoic acid) and gamma-vinyl GABA (4-amino-hex-5-enoic acid). Psychopharacol 59:47–50
Michelucci R, Tassinari CA (1989) Response to vigabatrin in relation to seizure type. Br J Clin Pharmacol 27 [Suppl 1]:119S–124S
Michelucci R, Plasmati RM Larmeggiani L et al. (1991) Single-blind placebo-controlled dose modification study of vigabatrin in patients with refractory epilepsy. Epilepsia 32 [Suppl 1]:S102
Michelucci R, Veri L, Passarelli D et al. (1994) Long-term follow-up study of vigabatrin in the treatment of refractory epilepsy. J Epilepsy 7:88–93
Mumford JP.(1994) Epilepsy, pregnancy and vigabatrin. Intern Med Newslet 2:2–4
Mumford JP.(1988) A profile of vigabatrin. Br J Clin Pract 42 [Suppl 61]:7–9
Mumford JP, Dam M (1989) Meta-analysis of placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 27:101S–107S
Otto FG, Egli M (1991) Effect of vigabatrin (gamma-vinyl GABA) on partial attacks of various localizations. In: Scheffner D (ed) Epilepsy 90. Einhoen-Presse Verlag, Reinbek, pp. 230–232
Palfreyman MG, Böhlen P, Huot S, Mellet M (1980) The effect of gamma-vinyl GABA and gamma-acetylenic GABA on the concentration of homocarnosine in brain and CSF of the rat. Brain Res 190:288–292
Penry JK, Wilder BJ, Sachdeo RC et al. (1993) Multicenter dose-response study of vigabatrin in adults with focal (partial) epilepsy. Epilepsia 34 [Suppl 6]:67
Petroff OAC, Rothman DL, Behar KL, Mattson RH (1995) Initial observations of effect of vigabatrin on in vivo 1H spectroscopic measurements of γ-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia 36:457–464
Petroff OAC, Rothman DL, Behar KL, Collins BA, Mattson RH (1996a) Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 47:1567–1571
Petroff OAC, Rothman DL, Behar KL, Mattson RH (1996b) Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 46:1459–1463
Piredda S, Lim CR, Gale K (1985) Intracerebral site of convulsant action of bicuculline. Life Sci 56:1295–1298
Pitkänen A, Halonen T (1995) Prevention of neuronal cell death by anticonvulsants in experimental epilepsy (extended abstract) Acta Neurol Scand [Suppl] 162:22–23
Pitkänen A, Halonen T, Ylinen A, Riekkinen P (1987) Somatostatin, β-endorphin, and prolactin levels in human cerebrospinal fluid during the gamma-vinyl GABA treatment of patients with complex partial seizures. Neuropeptides 9:185–195
Provinviali L, Bartolini M, Mari F et al. (1996) Influence of vigabatrin on cognitive performance and behaviour in patients with drug resistant epilepsy. Acta Neurol Scand 94:12–18
Remy C, Beaumont D (1989) Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 27 [Suppl 1]:125S–129S
Remy C, Favel P, Tell G (1986) Double-blind, placebo-controlled, crossover study of vigabatrin in drug resistant epilepsy of the adult. Boll Lega Ital Epil 54/55:241–243
Rey E, Pons G, Richard MO, et al. (1990) Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. Br J Clin Pharmac 30:253–257
Reynolds EH, Ring HA, Farr IN, Heller AJ, Elwes RDC (1991) Open, double-blind and long-term study of vigabatrin in chronic epilepsy. Epilepsia 32:530–538
Richens A (1991) Pharmacology and clinical pharmacology of vigabatrin. J Child Neurology 6:2S7–2S10
Ried S, Schmidt D, Stodieck SRG et al. (1991) Vigabatrin in pharmaco-resistant epilepsies: a single-blind placebo-controlled study. In: Scheffner E (ed) Epilepsy 90. Einhorn-Presse Verlag, Reinbek, pp. 233–237
Rimmer EM, Richens A (1984) Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 189–190
Rimmer EM, Richens A (1989) Interaction between vigabatrin and phenytoin. Br J Clin Pharmac 27:27S–33S
Saletu B, Grunberger J, Linzmayer L et al. (1986) Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA transaminase inhibitor. Intern J Psychophysiol 4:63–80
Sander JWAS, Hart YM (1990) Vigabatrin and behavior disturbances. Lancet 335:57
Sander JWAS, Hart YM, Trimble MR, Shorvon SD (1991) Behavioral disturbances associated with vigabatrin therapy. Epilepsia 32 [Suppl 1]:12
Schechter PJ (1986) Vigabatrin. In: Meldrum B, Porter RJ (eds) New anticonvulsant drugs. Libby, London, pp. 265–275
Schechter PJ, Tranier Y (1977) Effect of elevated brain GABA concentrations of the actions of bicuculline and picrotoxin in mice. Psychopharmacol 54:145–148
Schechter PJ, Tranier Y, Grove J (1979) Attempts to correlate alterations in brain GABA metabolism by GABA-T inhibitors with their anticonvulsant effects. In: Mandel P, DeFeudes FV (eds) GABA-biochemistry and CNS Functions. Plenum Press, New York, pp. 43–57
Schechter PJ, Hanke NFJ, Grove J et al. (1984) Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 34: 34–39
Shin C, Rigsbee LC, McNamara JO (1986) Anti-seizure and anti-epileptogenic effect of gamma-vinyl gamma-aminobutyric acid in amygdaloid kindling. Brain Res 398:370–374
Sivenius MRJ, Ylinen A, Murros K, Matilainen R, Riekkinen P (1987) Double-blind dose-reduction study of vigabatrin in complex partial epilepsy. Epilepsia 28:688–692
Sivenius J, Ylinen A, Murros K, Mumford JP, Riekkinen PJ (1991) Efficacy of vigabatrin in drug-resistant partial epilepsy during a 6-year follow-up period. Epilepsia 32 [Suppl 1]:11
Stevens JR, Phillips I, de Beaurepaire R (1988) Gamma-vinyl GABA in endopiriform area suppresses kindled amygdala seizures. Epilepsia 29:404–411
Tanganelii P, Regesta, G (1996) Vigabatrin versus carbamazepine monotherapy in newly diagnosed epilepsy: a randomized response conditional cross-over study. Epilepsy Res 25:257–262
Tartara A, Manni A, Galimberti CA et al. (1986) Vigabatrin in the treatment of epilepsy: a double-blind placebo controlled study. Epilepsia 27:717–723
Tartara A, Manni A, Galimberti CA et al. (1989) Vigabatrin in the treatment of epilepsy: a long-term follow-up study. J Neurol Neurosurg Psychiatry 52:467–471
Tassinari CA, Michelucci R, Ambroseetto G et al. (1987) Double-blind study of vigabatrin in the treatment of drug resistant epilepsy. Arch Neurol 44:907–910
Tsanacilis LM, Wicks J, Williams J, Richens A (1991) Determination of vigabatrin in plasma by reversed-phase high performance liquid chromatography. Ther Drug Monitor 13:251–253
Uldall P, Alving J, Gram L, Hogenhaven H (1995) Vigabatrin in childhood epilepsy: a 5-year follow-up study. Neuropediatrics 26:253–256
Wolf P (1993) The use of antiepileptic drugs in epileptology with respect to psychiatry. Neuropsychobiol 27:127–131
Ylinen A, Miettinen R, Pitkänen A, Gulyas A, Freund TF, Riekkinen PJ (1991) Enhanced GABAergic inhibition preserves hippocampal structure and function in a model of epilepsy. Proc Natl Acad Sci USA 88:7650–7653
Zaccara G, Ludice AA, Mumford J (1990) Vigabatrin as add on treatment in refractory epilepsy. A multicenter placebo-controlled study. Second International Cleveland Clinic Epilepsy Symposium. Cleveland Ohio. Abstract book:18
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ben-Menachem, E. (1999). Vigabatrin. In: Eadie, M.J., Vajda, F.J.E. (eds) Antiepileptic Drugs. Handbook of Experimental Pharmacology, vol 138. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60072-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-60072-2_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64244-9
Online ISBN: 978-3-642-60072-2
eBook Packages: Springer Book Archive